Study of New Determinants of Type 2 Diabetes in Severe Obesity

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This project aims at identifying new determinants of type 2 diabetes in severe obesity. To do so, a biological collection, including tissues of interest in the field of metabolism, will be collected during bariatric surgery in obese patients. Three different groups of metabolic status of patients, corresponding to different stages of evolution of the disease, will be constituted: type 2 diabetes, insulin resistance, insulin sensitivity. The main objective is to compare, between these 3 groups of patients, several biological processes that may be involved in the pathophysiology of type 2 diabetes and disorders associated with obesity, including: * Abnormalities of the transcriptome, proteome, metabolome in all target tissues (plasma, serum, muscle, subcutaneous and visceral adipose tissue, omental artery, liver) * Identification of metabolic signatures, protein and miRNA in plasma * Immunoinflammatory response in adipose tissue * Polymorphisms SNP from whole blood * Histological analysis of tissue sections This main objective will be studied on samples taken at the time of surgery Secondary objectives will be to study the changes in metabolites, proteins and miRNA in plasma level 3 and 12 months after the completion of surgery, according to the initial metabolic state.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Written informed consent

• Age 18 - 65 years inclusive at surgery

• IMC \> 35

• Subject qualified for bariatric surgery (sleeve gastrectomy or gastric bypass)

• Specific criteria :

‣ Type 2 diabetes group (D) (90 patients) : type 2 diabetes according to ADA criteria

⁃ Insulin resistance non diabetes group (IR) (80 patients) : HOMA-IR criteria ≥ 3

⁃ Insulin Sensitivity non diabetes group (N) (100 patients) : N1.HOMA-IR criteria \< 3

∙ Non inclusion Criteria:

• Vulnerability according to article L1121-6 of the Public Health Code

• Protected adult or unability to give consent according to article L1121-8 of the Public Health Code

• Unability to understand the design and aims of the study or to communicate with the investigator

• Non affiliation to a social security system

• Prior bariatric surgery (except lap-band procedure)

• Serologic profile indicating hepatitis B, hepatitis C or HIV infection

• Inflammatory, infectious or autoimmune disease (current or in the previous 3 month)

• Malignancies within 5 years prior to inclusion or not considered as treated curatively

• Concomitant use of steroids or NSAI or use in the 8 days before surgery

⁃ alcohol abuse/addiction

⁃ Anticipated poor compliance to study procedures

⁃ Other type of diabetes than type 2

Locations
Other Locations
France
Hôpital Saint Eloi
RECRUITING
Montpellier
Contact Information
Primary
Florence Galtier, MD
f-galtier@chu-montpellier.fr
Time Frame
Start Date: 2016-02-02
Estimated Completion Date: 2028-09
Participants
Target number of participants: 270
Treatments
Type 2 diabetes
Type 2 diabetes according to ADA criteria
Insulin resistance non diabetes
HOMA-IR criteria ≥ 3
Insulin sensitivity non diabetes
HOMA-IR criteria \< 3
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Montpellier

This content was sourced from clinicaltrials.gov